<DOC>
	<DOC>NCT01182142</DOC>
	<brief_summary>Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.</brief_summary>
	<brief_title>Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>histologically confirmed nonclear cell renal cell carcinoma confirmed metastatic sites no chemotherapy in history metastases in CNS previous targeted therapy other tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>